动态敏感对比磁共振(DSC-MRI)用于高级别胶质瘤专家共识2020

2020-06-12 欧洲癌症治疗研究组织 Neuro Oncol . 2020 Jun 9;noaa141. doi: 10.1093/neuonc/noaa141.

尽管动态敏感性造影剂(DSC)MRI在临床上得到了广泛的应用,但DSC-MRI方法尚未标准化,阻碍了其在多中心试验中用于反应评估。近日,Jumpstarting脑肿瘤药物开发联盟的DSC-MRI标准化

中文标题:

动态敏感对比磁共振(DSC-MRI)用于高级别胶质瘤专家共识2020

发布日期:

2020-06-12

简要介绍:

尽管动态敏感性造影剂(DSC)MRI在临床上得到了广泛的应用,但DSC-MRI方法尚未标准化,阻碍了其在多中心试验中用于反应评估。近日,Jumpstarting脑肿瘤药物开发联盟的DSC-MRI标准化小组委员会发布了与BTIP兼容的最新共识DSC-MRI方案,BTIP是高等级胶质瘤的标准化脑肿瘤成像方案,越来越多地用于临床,是国家临床试验网络的默认MRI方案。在回顾了DSC-MRI协议的争议基础后,本手稿提供了委员会确定的基于证据的临床DSC-MRI最佳实践,包括脉冲序列(梯度回波与自旋回波)、符合BTIP的造影剂剂量(预负荷和栓塞)、翻转角(FA)、回波时间(TE)和后处理漏诊。综上所述,全剂量预负荷、全剂量栓塞剂量使用中间(60°)FA和场强依赖性TE(1.5T时40-50ms,3T时20-35ms)为脑血容量估计提供了总体最佳的准确性和精确度。当需要使用单剂量造影剂时,使用低FA(30°)和场强依赖性TE的无预载、全剂量栓剂给药可提供出色的性能,减少造影剂的使用量,并消除预载剂量和潜伏时间变化带来的潜在系统误差。

相关资料下载:
[AttachmentFileName(sort=1, fileName=10.1016@j.jand.2020.04.020.pdf)] GetToolGuiderByIdResponse(projectId=1, id=6b12d1c001918e8c, title=动态敏感对比磁共振(DSC-MRI)用于高级别胶质瘤专家共识2020, enTitle=, guiderFrom=Neuro Oncol . 2020 Jun 9;noaa141. doi: 10.1093/neuonc/noaa141., authorId=0, author=, summary=尽管动态敏感性造影剂(DSC)MRI在临床上得到了广泛的应用,但DSC-MRI方法尚未标准化,阻碍了其在多中心试验中用于反应评估。近日,Jumpstarting脑肿瘤药物开发联盟的DSC-MRI标准化, cover=, journalId=0, articlesId=null, associationId=355, associationName=欧洲癌症治疗研究组织, associationIntro=null, copyright=0, guiderPublishedTime=Fri Jun 12 00:00:00 CST 2020, originalUrl=, linkOutUrl=, content=<p>尽管动态敏感性造影剂(DSC)MRI在临床上得到了广泛的应用,但DSC-MRI方法尚未标准化,阻碍了其在多中心试验中用于反应评估。近日,Jumpstarting脑肿瘤药物开发联盟的DSC-MRI标准化小组委员会发布了与BTIP兼容的最新共识DSC-MRI方案,BTIP是高等级胶质瘤的标准化脑肿瘤成像方案,越来越多地用于临床,是国家临床试验网络的默认MRI方案。在回顾了DSC-MRI协议的争议基础后,本手稿提供了委员会确定的基于证据的临床DSC-MRI最佳实践,包括脉冲序列(梯度回波与自旋回波)、符合BTIP的造影剂剂量(预负荷和栓塞)、翻转角(FA)、回波时间(TE)和后处理漏诊。综上所述,全剂量预负荷、全剂量栓塞剂量使用中间(60&deg;)FA和场强依赖性TE(1.5T时40-50ms,3T时20-35ms)为脑血容量估计提供了总体最佳的准确性和精确度。当需要使用单剂量造影剂时,使用低FA(30&deg;)和场强依赖性TE的无预载、全剂量栓剂给药可提供出色的性能,减少造影剂的使用量,并消除预载剂量和潜伏时间变化带来的潜在系统误差。</p>, tagList=[TagDto(tagId=251, tagName=MRI), TagDto(tagId=691, tagName=胶质瘤)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=40, categoryName=影像放射, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=0, guiderKeyword=, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=4, opened=0, paymentType=, paymentAmount=18, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=5158, appHits=120, showAppHits=0, pcHits=1437, showPcHits=5038, likes=2, shares=5, comments=2, approvalStatus=1, publishedTime=Sat Jun 13 21:37:03 CST 2020, publishedTimeString=2020-06-12, pcVisible=1, appVisible=1, editorId=4754896, editor=fbzhang, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=fbzhang, createdTime=Sat Jun 13 21:36:55 CST 2020, updatedBy=4754896, updatedName=fbzhang, updatedTime=Sat Jan 06 19:26:15 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=10.1016@j.jand.2020.04.020.pdf)])
10.1016@j.jand.2020.04.020.pdf
下载请点击:
评论区 (2)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=954577, encodeId=cd509545e75f, content=资料好好,但无法分享,遗憾!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1bc65476534, createdName=ms6000001015893838, createdTime=Wed Apr 07 13:46:47 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882098, encodeId=df2f882098df, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c2e25206552, createdName=1474e843m09暂无昵称, createdTime=Wed Sep 02 08:47:17 CST 2020, time=2020-09-02, status=1, ipAttribution=)]
    2021-04-07 ms6000001015893838

    资料好好,但无法分享,遗憾!

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=954577, encodeId=cd509545e75f, content=资料好好,但无法分享,遗憾!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1bc65476534, createdName=ms6000001015893838, createdTime=Wed Apr 07 13:46:47 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882098, encodeId=df2f882098df, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c2e25206552, createdName=1474e843m09暂无昵称, createdTime=Wed Sep 02 08:47:17 CST 2020, time=2020-09-02, status=1, ipAttribution=)]
    2020-09-02 1474e843m09暂无昵称

    学习

    0